Editas Medicine

Editas Medicine Appoints Cynthia Collins President & CEO
Editas Medicine Appoints Cynthia Collins President & CEO
Xconomy
Editas Medicine
Flag link:
Editas, Allergan launch first in vivo study of CRISPR-based medicine
Editas, Allergan launch first in vivo study of CRISPR-based medicine
BioPharma Dive
Editas Medicine
Allergan
clinical trials
CRISPR
EDIT-101
Flag link:
Should Sangamo's Failure Make CRISPR Investors Nervous?
Should Sangamo's Failure Make CRISPR Investors Nervous?
Motley Fool
Sangamo Therapeutics
gene editing
CRISPR
CRISPR Therapeutics
Editas Medicine
Flag link:
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
Xconomy
Editas Medicine
Katrine Bosley
CRISPR
Flag link:
FDA signs off on Editas CRISPR study on patients with a rare genetic disorder
FDA signs off on Editas CRISPR study on patients with a rare genetic disorder
Stat
CRISPR
Editas Medicine
FDA
Flag link:
Here's Why CRISPR Stocks Fell as Much as 40.7% in October
Here's Why CRISPR Stocks Fell as Much as 40.7% in October
Motley Fool
CRISPR
CRISPR Therapeutics
Editas Medicine
Intellia Therapeutics
Flag link:
Allergan and Editas exercise CRISPR option
Allergan and Editas exercise CRISPR option
Biopharma Dive
Allergan
Editas Medicine
CRISPR
EDIT-101
gene editing
Flag link:
Here's Why CRISPR Stocks Are Down as Much as 11.4% Today
Here's Why CRISPR Stocks Are Down as Much as 11.4% Today
Motley Fool
CRISPR
CRISPR Therapeutics
Editas Medicine
Intellia Therapeutics
Flag link:
CRISPR Could Cause Cancer? Here Are 3 Reasons Investors Shouldn't Panic
CRISPR Could Cause Cancer? Here Are 3 Reasons Investors Shouldn't Panic
Motley Fool
CRISPR
CRISPR Therapeutics
Editas Medicine
Intellia Therapeutics
Flag link:
Here's Why the Top CRISPR Stocks Rose as Much as 47.1% in May
Here's Why the Top CRISPR Stocks Rose as Much as 47.1% in May
Motley Fool
CRISPR
Editas Medicine
Intellia Therapeutics
CRISPR Therapeutics
Flag link:
Editas Medicine Starts a "Transformative" Year on a High Note
Editas Medicine Starts a "Transformative" Year on a High Note
Motley Fool
Editas Medicine
earnings
CRISPR
Flag link:
Disruptor Alert: These 5 Companies Are Changing Healthcare
Disruptor Alert: These 5 Companies Are Changing Healthcare
Motley Fool
CRISPR Therapeutics
Editas Medicine
Illumina
IBM
Intellia Therapeutics
gene editing
gene sequencing
artificial intelligence
Flag link:
What Happened in Biotech in 2016?
What Happened in Biotech in 2016?
Motley Fool
biotech
M&A
biosimilars
IPOs
Editas Medicine
CRISPR Therapeutics
Pfizer
Medivation
Celgene
Juno Therapeutics
Sarepta Therapeutics
Flag link:
Why CRISPR Is An Attractive Approach To Treat Sickle Cell Disease
Why CRISPR Is An Attractive Approach To Treat Sickle Cell Disease
Forbes
CRISPR
sickle cell disease
Editas Medicine
Novartis
Intellia Therapeutics
Flag link:
CRISPR patent fight: The legal bills are soaring
CRISPR patent fight: The legal bills are soaring
Stat
CRISPR
patents
SEC
Editas Medicine
Flag link:
Biotech's Top 5 Stock Winners, And Losers, In Q1 2016
Biotech's Top 5 Stock Winners, And Losers, In Q1 2016
Forbes
biotech
PTC Therapeutics
Celldex Therapeutics
Biocryst
Puma Biotechnology
Portola Pharmaceuticals
MedicNova
BioTie Therapies
Editas Medicine
AveXis
Inovio
Flag link:
In CRISPR patent case, all eyes turn to the judge, a former scientist
In CRISPR patent case, all eyes turn to the judge, a former scientist
Stat
patents
CRISPR
genome editing
Intellia Therapeutics
Editas Medicine
CRISPR Therapeutics
Flag link:
Biotechs launch an IPO blitz as Nasdaq stumbles out of the gate
Biotechs launch an IPO blitz as Nasdaq stumbles out of the gate
Fierce Biotech
biotech
IPOs
Editas Medicine
Syndax Pharma
Audentes Therapeutics
Bavarian Nordic
Corvus Pharmaceuticals
Reata Pharmaceuticals
Flag link:
Bill Gates And 13 Other Investors Pour $120 Million Into Revolutionary Gene-Editing Startup
Bill Gates And 13 Other Investors Pour $120 Million Into Revolutionary Gene-Editing Startup
Forbes
Bill Gates
gene editing
CRISPR-Cas9
Editas Medicine
Juno Therapeutics
Flag link:
CAR-T powerhouse Juno allies with gene-editing upstart Editas in $737M deal
CAR-T powerhouse Juno allies with gene-editing upstart Editas in $737M deal
Fierce Biotech
Juno Therapeutics
CAR-T
gene editing
Editas Medicine
Flag link:

Pages